argenx(ARGX) - 2022 Q2 - Earnings Call Presentation

Financial Performance - Argenx reported Q2 2022 net product revenues of $75 million[9], primarily driven by VYVGART sales[25] - US product net sales were $73.2 million in Q2 2022[20] - Japan product net sales were $1.5 million in Q2 2022[20] - The company ended Q2 with $2.6 billion in cash[7, 21] - R&D expenses for the second quarter were $126.9 million[21] - SG&A expenses for the second quarter were $127.8 million[21] VYVGART Launch and Expansion - Approximately 1400 patients are on VYVGART globally[27] - 85% of covered lives have broad coverage for VYVGART[34] - A J-Code for VYVGART went into effect on July 1, 2022[34] Pipeline Progress - A BLA submission for subcutaneous efgartigimod (SC) in gMG is expected by the end of 2022[7, 11] - ADHERE (CIDP) data is expected in Q1 2023[7] - ADVANCE-SC (ITP) and ADDRESS (PV) data are expected in the second half of 2023[7]